ADAM10 and early-onset autosomal dominant Alzheimer disease: Thus, how ADAM10 gains catalytic competence in vivo by complete removal of the propeptide is unknown, but this is an important question in the understanding of Alzheimer’s disease where the α-secretase activity is outweighed by pathological cleavage by β- and γ-secretases [18, 32].